Modality
ASO
MOA
CGRPant
Target
MALT1
Pathway
Epigenetic
Asthma
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
~Mar 2017
→ ~Jun 2018
NDA/BLA
Sep 2018
→ Jul 2025
NDA/BLACurrent
NCT05508250
72 pts·Asthma
2018-09→2025-07·Completed
72 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-268mo agoPh3 Readout· Asthma
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2025-07-26 · 8mo ago
Asthma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05508250 | NDA/BLA | Asthma | Completed | 72 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |